^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Title:

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Published date:
03/22/2024
Excerpt:
...the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Excerpt:
...- Participants must have folate receptor alpha positive tumor expression as defined in the protocol...
Trial ID: